Global Benazepril Market Size By Type (Purity:Above98%, Purity:Above99%), By Application (Table Product, Capsule Product), By Region, And Segment Forecasts, 2023 to 2032

The Global Benazepril Market was valued at USD 920 million in 2023 and is projected to reach USD 1.52 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. Benazepril, an ACE (angiotensin-converting enzyme) inhibitor, is widely used for the treatment of hypertension, congestive heart failure, and kidney-related conditions, especially in diabetic patients. Increasing global prevalence of cardiovascular diseases and rising geriatric population are key drivers boosting market growth. Additionally, growing awareness about early diagnosis and treatment adherence, coupled with improvements in healthcare infrastructure across emerging markets, is further accelerating the demand for benazepril-based therapies.

Drivers:

1. Rising Prevalence of Cardiovascular and Renal Diseases

Benazepril plays a pivotal role in managing chronic conditions like hypertension and heart failure, which are increasingly prevalent due to sedentary lifestyles and poor dietary habits. The growing global burden of non-communicable diseases fuels demand for effective antihypertensive medications.

2. Growing Geriatric Population

Elderly individuals are more prone to chronic ailments requiring long-term medication such as benazepril. The expanding aging population, particularly in regions like Europe, Japan, and North America, significantly supports market growth.

3. Increasing Access to Generics

As branded benazepril patents expire, a wave of cost-effective generic versions has entered the market, improving drug accessibility and driving adoption in price-sensitive regions.

Restraints:

1. Side Effects and Safety Concerns

Despite its efficacy, benazepril can cause adverse reactions such as hyperkalemia, cough, dizziness, and angioedema, limiting its usage among certain patient groups and creating hesitation among prescribers.

2. Availability of Alternative Therapies

The presence of multiple classes of antihypertensive drugs such as ARBs, beta-blockers, and calcium channel blockers provides clinicians with several options, which may restrain the growth potential of benazepril.

Opportunity:

1. Emerging Markets and Expanding Health Insurance Coverage

Increasing healthcare access in Asia-Pacific, Latin America, and parts of Africa, along with broader insurance coverage, creates opportunities for growth through improved availability of benazepril and patient affordability.

2. Combination Therapy Development

There is a growing trend toward fixed-dose combination drugs, such as benazepril with amlodipine or hydrochlorothiazide, which offer enhanced efficacy and improved patient compliance, opening new revenue streams for pharmaceutical players.

Market by System Type Insights:

By drug type, Generic Benazepril accounted for the largest market share in 2023 due to its affordability and wide-scale availability after patent expiration. However, Fixed-Dose Combination Benazepril is anticipated to be the fastest-growing segment during the forecast period as combination therapies become the standard of care in chronic disease management.

Market by End-Use Insights:

The Hospital Pharmacies segment dominated the end-use market in 2023, accounting for over 40% of global revenue due to the critical nature of cardiovascular prescriptions being initiated and dispensed in clinical settings. Meanwhile, Online Pharmacies are expected to exhibit rapid growth due to increasing e-prescription adoption and direct-to-patient medication delivery services.

Market by Regional Insights:

North America led the market in 2023, driven by a high prevalence of hypertension, favorable reimbursement structures, and strong presence of major pharmaceutical firms. However, Asia-Pacific is projected to witness the highest CAGR during the forecast period due to growing health awareness, rapid urbanization, and expanding healthcare infrastructure in countries like China and India.

Competitive Scenario:

Prominent players in the Global Benazepril Market include Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Aurobindo Pharma, Apotex Inc., Glenmark Pharmaceuticals, Cipla Ltd., Torrent Pharmaceuticals, and Sun Pharmaceutical Industries Ltd. These firms are actively investing in product portfolio diversification, regulatory approvals, and global distribution expansions.

Key Developments:

In 2023, Lupin launched a generic version of benazepril-hydrochlorothiazide in the U.S. market to target hypertensive patient populations.

In 2024, Teva Pharmaceuticals received FDA approval for a new benazepril formulation with enhanced bioavailability.

In 2025, Cipla expanded its cardiovascular therapeutic segment by introducing benazepril under a new chronic care division focused on rural healthcare.

Scope of Work – Global Benazepril Market

FAQs:

1) What is the current market size of the Global Benazepril Market?

The market size of the Global Benazepril Market in 2023 was USD 920 million.

2) What is the major growth driver of the Global Benazepril Market?

The rising prevalence of cardiovascular and renal diseases, particularly among the elderly, is the key growth driver.

3) Which is the largest region during the forecast period in the Global Benazepril Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Benazepril Market?

Generic benazepril dominated the market by drug type in 2023.

5) Who are the key market players in the Global Benazepril Market?

Major players include Novartis, Teva, Lupin, Aurobindo, Mylan, Cipla, Glenmark, and Sun Pharma.